Medical Services Expenditures by Disease: Infectious and Parasitic Diseases, Blended Account Basis (INFAPSEXPBLEND) | FRED | St. Louis Fed
- Rows
- 22
- Columns
- 2
- Data range
- 2000-01-01 to 2021-01-01
Graph and download economic data for Medical Services Expenditures by Disease: Infectious and Parasitic Diseases, Blended Account Basis (INFAPSEXPBLEND) from 2000 to 2021 about infection, disease, healthcare, medical, health, expenditures, services, and USA.
AI analysis
Dataset Analysis: Medical Services Expenditures for Infectious and Parasitic Diseases (INFAPSEXPBLEND)
1. Dataset Overview and Context
This dataset, sourced from the Federal Reserve Bank of St. Louis (FRED), tracks annual medical services expenditures specifically attributed to infectious and parasitic diseases on a "blended account basis" — a methodology that typically combines multiple payer perspectives (out-of-pocket, insurance, public programs) into a single expenditure estimate. The data spans 2000–2021 (22 annual observations), pulled via FRED's public API (fredgraph.csv). As a Federal Reserve-hosted series, this data likely originates from BEA/CMS health expenditure accounts and benefits from institutional rigor in methodology, though FRED typically republishes rather than originates such health-specific breakdowns. Its long time horizon and consistent single-metric focus make it valuable for time-series correlation studies against other macroeconomic or public health indicators, particularly for examining how infectious disease spending trends relative to GDP, healthcare CPI, or epidemiological events (e.g., H1N1 in 2009, COVID-19 in 2020).
2. Data Quality Observations
Data quality here is notably strong: zero null cells across both columns and all 22 rows, with full distinct-value counts (22 distinct dates, 22 distinct expenditure values) confirming no duplicate timestamps or repeated readings. The duplicate-row check is flagged as pending Phase D recomputation, so that verification is not yet finalized, but the absence of any null cells combined with a clean date range (2000-01-01 to 2021-01-01, annual cadence) suggests a well-maintained, complete series with no missing years. The one caveat is the empty sample data section — without visible raw rows, structural assumptions (e.g., exact units, currency, whether values are indexed or absolute dollars) cannot be independently verified and should be confirmed against the FRED source page before analysis.
3. Key Column Distributions
The core metric, INFAPSEXPBLEND, shows substantial variance and a right-skewed distribution (skewness = 1.54), indicating that spending grew disproportionately in later years rather than following a linear trend. Specifically: the mean (81.09) sits well above the median (67.04), a classic signature of a small number of high-value years pulling the average upward — consistent with 2 detected outliers, most plausibly 2020–2021 during the COVID-19 pandemic. The interquartile range (Q1=41.04, Q3=105.11) shows the bulk of "normal" years clustered in a moderate band, while the max (230.81) is roughly 3.4x the median, reinforcing that recent pandemic-era spending sharply diverged from the 2000–2018 baseline (min=24.68). This pattern makes the series an excellent candidate for structural break analysis or pre/post-2020 segmented correlation studies.
4. Recommended Join Keys
The observationdate column (Date type, 22 distinct values, no nulls) is the clear and only viable join key. Since this is annual data, cross-dataset joins should either (a) align to other annual series on exact year-start dates, or (b) require downsampling of higher-frequency datasets (monthly/quarterly) to annual averages/sums before joining. Analysts should confirm date alignment conventions (start-of-year vs. end-of-year stamps) when joining against other FRED series, as mismatched conventions can silently degrade correlation accuracy.
5. Recommended Companion Datasets
Strong candidates for correlation analysis include: (1) CPI for Medical Care Services (FRED: CPIMEDSL) to normalize spending against healthcare inflation; (2) Total National Health Expenditures (NHE) by disease category for share-of-total analysis; (3) CDC/WHO infectious disease incidence or mortality data to test spending-vs-outcome relationships; (4) U.S. GDP or PCE Healthcare series to compute expenditure-to-GDP ratios; and (5) Other FRED "EXPBLEND" disease-category series (e.g., circulatory, respiratory, neoplasms) to benchmark infectious disease spending against other categories and identify whether the 2020–2021 outlier spike was infectious-disease-specific or part of a broader healthcare spending surge.
Columns
- observation_date (date)
- INFAPSEXPBLEND (decimal)